LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,282
تعداد مقالات11,725
تعداد مشاهده مقاله82,705,055
تعداد دریافت فایل اصل مقاله121,597,535
Moradi, Omid, Arzhangzadeh, Alireza, Asadi, Sara, Nozhat, Salma, Mahmoudi, Laleh. (1404). Pharmacotherapy in Chronic Coronary Syndromes: Current Evidence and Future Directions.. سامانه مدیریت نشریات علمی, 12(1), 37-54. doi: 10.30476/tips.2025.108447.1316
Omid Moradi; Alireza Arzhangzadeh; Sara Asadi; Salma Nozhat; Laleh Mahmoudi. "Pharmacotherapy in Chronic Coronary Syndromes: Current Evidence and Future Directions.". سامانه مدیریت نشریات علمی, 12, 1, 1404, 37-54. doi: 10.30476/tips.2025.108447.1316
Moradi, Omid, Arzhangzadeh, Alireza, Asadi, Sara, Nozhat, Salma, Mahmoudi, Laleh. (1404). 'Pharmacotherapy in Chronic Coronary Syndromes: Current Evidence and Future Directions.', سامانه مدیریت نشریات علمی, 12(1), pp. 37-54. doi: 10.30476/tips.2025.108447.1316
Moradi, Omid, Arzhangzadeh, Alireza, Asadi, Sara, Nozhat, Salma, Mahmoudi, Laleh. Pharmacotherapy in Chronic Coronary Syndromes: Current Evidence and Future Directions.. سامانه مدیریت نشریات علمی, 1404; 12(1): 37-54. doi: 10.30476/tips.2025.108447.1316

Pharmacotherapy in Chronic Coronary Syndromes: Current Evidence and Future Directions.

Trends in Pharmaceutical Sciences and Technologies
مقاله 4، دوره 12، شماره 1، خرداد 2026، صفحه 37-54    اصل مقاله (515.21 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/tips.2025.108447.1316
نویسندگان
Omid Moradi1؛ Alireza Arzhangzadeh2؛ Sara Asadi1؛ Salma Nozhat2؛ Laleh Mahmoudi* 1
1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
2Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
چکیده
Chronic coronary syndromes (CCS) constitute a dynamic and heterogeneous spectrum of clinical manifestations that necessitate a comprehensive, patient-centered, and multidisciplinary management approach. Recent international guidelines for the management of patients with chronic coronary disease underscore a dual therapeutic paradigm that integrates rigorous, evidence-based lifestyle modifications with precisely targeted pharmacological interventions to optimize long-term cardiovascular outcomes. Non-pharmacological lifestyle strategies—such as structured exercise programs, dietary optimization, smoking cessation, and psychosocial support—form the cornerstone of cardiovascular risk reduction and have been shown to exert synergistic benefits when combined with pharmacotherapy. This narrative review aims to synthesize and critically appraise current evidence and consensus recommendations on the pharmacological management of CCS, with particular emphasis on mechanisms of action, comparative clinical effectiveness, safety profiles, and the evolving landscape of emerging therapies. The discussion encompasses established drug classes, including antianginal agents, lipid-lowering therapies, antithrombotic agents, and neurohormonal modulators, while also examining novel compounds such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, and bempedoic acid, which represent significant advances in lipid management. By integrating findings from recent landmark clinical trials with guideline-directed recommendations, this manuscript delivers a comprehensive and clinically relevant overview intended to inform and support the decision-making of cardiologists, clinical pharmacists, and researchers engaged in the field of cardiovascular therapeutics.

تازه های تحقیق

Omid Moradi (Google Scholar)
Laleh Mahmoudi (Google Scholar)

کلیدواژه‌ها
Chronic coronary syndrome؛ Cardiology؛ Pharmacy؛ Lipid-lowering therapy؛ PCSK9 inhibitors؛ lifestyle modification
مراجع
1.    Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. 
2.    Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039. 
3.    Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74. doi: 10.1038/nature01323. 
4.    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-65. doi: 10.1056/NEJMoa021993. PMID: 12432042.
5.    Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914. 
6.    Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC State-of-the-Art review. J Am Coll Cardiol. 2018;72(21):2625-41. doi: 10.1016/j.jacc.2018.09.042. 
7.    Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary atherosclerotic plaque regression: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(1):66-82. doi: 10.1016/j.jacc.2021.10.035. 
8.    Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. Erratum in: Eur Heart J. 2025;46(16):1565. doi: 10.1093/eurheartj/ehaf079. 
9.    Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):563-95. doi: 10.1161/CIR.0000000000000677. 
10.    Ding N, Sang Y, Chen J, Ballew SH, Kalbaugh CA, Salameh MJ, et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol. 2019;74(4):498-507. doi: 10.1016/j.jacc.2019.05.049. 
11.    Guasch-Ferré M, Willett WC. The Mediterranean diet and health: a comprehensive overview. J Intern Med. 2021;290(3):549-66. 
12.    Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10. doi: 10.1056/NEJM200101043440101. 
13.    Yubero-Serrano EM, Fernandez-Gandara C, Garcia-Rios A, Rangel-Zuñiga OA, Gutierrez-Mariscal FM, Torres-Peña JD, et al. Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial. PLoS Med. 2020;17(9):e1003282. doi: 10.1371/journal.pmed.1003282. 
14.    Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens. 1994;7(7 Pt 2):7S-12S. doi: 10.1093/ajh/7.7.7s. PMID: 7946184.
15.    Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med. 2005;165(20):2355-60. doi: 10.1001/archinte.165.20.2355. 
16.    Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44(6):452-469. doi: 10.1093/eurheartj/ehac747. 
17.    Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867-72. doi: 10.1001/archinte.162.16.1867. 
18.    Jensen RV, Hjortbak MV, Bøtker HE. Ischemic heart disease: An update. Seminars in nuclear medicine. Semin Nucl Med. 2020;50(3):195-207.
19.    Frishman WH. β-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013;18(4):310-9. doi: 10.1177/1074248413484986. 
20.    Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, et al. The evolving role of calcium channel blockers in hypertension management: Pharmacological and clinical considerations. Curr Issues Mol Biol. 2024;46(7):6315-6327. doi: 10.3390/cimb46070377. 
21.    Nossaman VE, Nossaman BD, Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev. 2010;18(4):190-7. 
22.    Deedwania P. Selective and specific inhibition of if with ivabradine for the treatment of coronary artery disease or heart failure. Drugs. 2013;73(14):1569-86. doi: 10.1007/s40265-013-0117-0. 
23.    Aldiwani H, Mahdai S, Alhatemi G, Bairey Merz CN. Microvascular angina: diagnosis and management. Eur Cardiol. 2021;16:e46. doi: 10.15420/ecr.2021.15. 
24.    Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013;112(1):8-13. doi: 10.1016/j.amjcard.2013.02.045. 
25.    Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, et al. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart. 2018;5(1):e000725. doi: 10.1136/openhrt-2017-000725. 
26.    Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372(9646):1335-41. doi: 10.1016/S0140-6736(08)61554-8. 
27.    Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038-45. doi: 10.1016/j.jacc.2013.02.011. 
28.    Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75. doi: 10.1016/j.jacc.2006.05.044. 
29.    Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. 
30.    Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229-43. doi: 10.1161/CIRCRESAHA.116.308537. Erratum in: Circ Res. 2018 Sep 28;123(8):e20. doi: 10.1161/RES.0000000000000228. 
31.    Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. 
32.    Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80. doi: 10.1001/jama.291.9.1071. PMID: 14996776.
33.    Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. doi: 10.1056/NEJMoa1110874. 
34.    Shaya FT, Sing K, Milam R, Husain F, Del Aguila MA, Patel MY. Lipid-Lowering efficacy of ezetimibe in patients with atherosclerotic cardiovascular disease: A systematic review and meta-analyses. Am J Cardiovasc Drugs. 2020;20(3):239-48. doi: 10.1007/s40256-019-00379-9. 
35.    Lee SH, Lee YJ, Heo JH, Hur SH, Choi HH, Kim KJ, et al. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis. J Am Coll Cardiol. 2023;81(14):1339-49. doi: 10.1016/j.jacc.2023.02.007. 
36.    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. doi: 10.1056/NEJMoa1615664. 
37.    Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500-9. doi: 10.1056/NEJMoa1500858. 
38.    Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. doi: 10.1056/NEJMoa1801174. 
39.    Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(27):2362-76. doi: 10.1093/eurheartj/ehae324. 
40.    Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in coronary artery disease: A daunting dilemma. J Clin Med. 2018;7(4):74. doi: 10.3390/jcm7040074.
41.    Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. doi: 10.1016/S0140-6736(17)32458-3. 
42.    Xiao-Dong Z, Fei-Fei L, Zhan-Peng W, Xin-Xue L, Zhi-Min D. Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention. Ther Adv Cardiovasc Dis. 2016;10(3):172-7. doi: 10.1177/1753944716648851. 
43.    López-Miranda J. Efficacy, benefit and safety of inclisiran. Clin Investig Arterioscler. 2024;36:24-30. English, Spanish. doi: 10.1016/j.arteri.2024.07.003. 
44.    Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-19. doi: 10.1056/NEJMoa1912387. 
45.    Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharmacol. 2023;14:1260921. doi: 10.3389/fphar.2023.1260921. 
46.    Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353-64. doi: 10.1056/NEJMoa2215024. 
47.    Venkatraman S, Das S, Eerike M, Cherian JJ, Bagepally BS. Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2023;79(11):1453-63. doi: 10.1007/s00228-023-03555-8. 
48.    Bays HE, Bloedon L, Brennan D, Lei L, Lincoff AM, Nicholls SJ, et al. Bempedoic acid for prevention of cardiovascular events in people with obesity: A CLEAR outcomes subset analysis. J Am Heart Assoc. 2025;14(4):e037898. doi: 10.1161/JAHA.124.037898. 
49.    Ridker PM, Lei L, Louie MJ, Haddad T, Nicholls SJ, Lincoff AM, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance. Circulation. 2024;149(1):28-35. doi: 10.1161/CIRCULATIONAHA.123.066213. 
50.    Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: In-depth review. Circulation. 2022;145(1):61-78. 
51.    Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting lipoprotein(a): Can RNA therapeutics provide the next step in the prevention of cardiovascular disease? Cardiol Ther. 2024;13(1):39-67. doi: 10.1007/s40119-024-00353-w. 
52.    Rakocevic J, Dobric M, Borovic ML, Milutinovic K, Milenkovic S, Tomasevic M. Anti-inflammatory therapy in coronary artery disease: Where do we stand? Rev Cardiovasc Med. 2023;24(1):10. doi: 10.31083/j.rcm2401010. 
53.    Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619-28.  
54.    Vallejo S, Palacios E, Romacho T, Villalobos L, Peiró C, Sánchez-Ferrer CF. The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2014;13:158. doi: 10.1186/s12933-014-0158-z. 
55.    Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115(3):288-92. doi: 10.1016/j.amjcard.2014.11.003. 
56.    Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060-2069. 
57.    Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117(11):e138-e140. doi: 10.1093/cvr/cvab231. 
58.    Bergonzini M, Loreni F, Lio A, Russo M, Saitto G, Cammardella A, et al. Panoramic on epigenetics in coronary artery disease and the approach of personalized medicine. Biomedicines. 2023;11(10):2864. doi: 10.3390/biomedicines11102864.
59.    Palatini P, Faria-Neto JR, Santos RD. The clinical value of β-blockers in patients with stable angina. Curr Med Res Opin. 2024;40(sup1):33-41. doi: 10.1080/03007995.2024.2317443. 
60.    Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ, et al. Anti-anginal drugs: Systematic review and clinical implications. Int J Cardiol. 2019;283:55-63. doi: 10.1016/j.ijcard.2018.12.008. 
61.    Montelaro BM, Ibrahim R, Thames M, Mehta PK. Optimal medical therapy for stable ischemic heart disease: Focus on anti-anginal therapy. Med Clin North Am. 2024;108(3):455-68. doi: 10.1016/j.mcna.2023.12.006. 
62.    Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43. doi: 10.1161/hc0902.104353. 
63.    Chen C, Li X, Su Y, You Z, Wan R, Hong K. Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: “Real-world” evidence. Clin Cardiol. 2022;45(12):1220-8.
64.    Abdulrhim S, Sankaralingam S, Ibrahim MIM, Awaisu A. The impact of pharmacist care on diabetes outcomes in primary care settings: An umbrella review of published systematic reviews. Prim Care Diabetes. 2020 Oct;14(5):393-400. doi: 10.1016/j.pcd.2019.12.007. 
65.    El Hajj MS, Jaam MJ, Awaisu A. Effect of pharmacist care on medication adherence and cardiovascular outcomes among patients post-acute coronary syndrome: A systematic review. Res Social Adm Pharm. 2018;14(6):507-520. doi: 10.1016/j.sapharm.2017.06.004.
66.    Omboni S, Caserini M. Effectiveness of pharmacist's intervention in the management of cardiovascular diseases. Open Heart. 2018;5(1):e000687. doi: 10.1136/openhrt-2017-000687. 
67.    Rattanavipanon W, Chaiyasothi T, Puchsaka P, Mungkornkaew R, Nathisuwan S, Veettil SK, et al. Effects of pharmacist interventions on cardiovascular risk factors and outcomes: An umbrella review of meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022;88(7):3064-77. doi: 10.1111/bcp.15279. 

آمار
تعداد مشاهده مقاله: 183
تعداد دریافت فایل اصل مقاله: 2


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب